Table 2.

Targeted therapies in TET patients, including thymomas and thymic carcinomas (TCs) [61, 65–71]

Drug	Target	Response rate	TTP/PFS	Reference
Gefitinib	EGFR	4%	4 months	Kurup et al. 2005
Imatinib	KIT	0%	3 months	Palmieri et al. 2012
Belinostat	HDAC	0% and 8%*	5.8 months	Giaccone et al 2011
Saracatinib	SRC	0%	5.3 months	Gubens et al. 2015
Buparlisip	PI3K	7%	11.1 months	Zaid et al. 2018
Everolimus	mTOR	12%	10.1 months	Zucali et al. 2018
Sunitinib	KIT, VEGFR, PDGFR	6% and 26%**	7.2 months	Thomas et al. 2015
Milciclib	CDK4/6	3.3% and 4.2%***	5.6 and 5.7 months	Besse et al. 2018***

*8% in thymomas, 0% in TCs; **6% in thymomas, 26% in TC patients; ***two trials with 102 cases overall, including 37 thymomas (see also [1])